Day2 Blood Cancers Today #HOPLive session on newly diagnosed MM #mmsm Saad Z. Usmani MD MBA FACP 🇺🇸🇵🇰 Binod Dhakal

Our superstar Binod Dhakal Blood Cancers Today #HOPLive smoldering #myeloma session #mmsm Saad Z. Usmani MD MBA FACP 🇺🇸🇵🇰 Sham Mailankoy

With a data cutoff date of April 30, 2025, cemsidomide at a dose of 100 µg once daily produced an overall response rate of 50% among 10 evaluable patients. #mmsm | Binod Dhakal cancernetwork.com/view/cemsidomi…

Want to hear about a D-domain BCMA-directed CAR-T construct, RAPA-201 (a polyclonal autologous T-cell therapy), & the feasibility of outpatient #CARTCell programs? Then stay tuned for our insightful interview with Binod Dhakal (Binod Dhakal) from #COMy2025!🎥 #MMSM #ImmunoOnc

⁦COMy⁩ ⁦MCW Cancer Center⁩ ⁦Medical College of Wisconsin⁩

EHA Library - The official digital education library of European Hematology Association (EHA)! Highly impressive activity of this novel bcl2 inhibitor in MM; excited to present poster at EHA and oral@at Lugano ⁦MCW Cancer Center⁩ ⁦ library.ehaweb.org/eha/2025/eha20…

This weekend, catch up on the latest podcasts and interviews from #HOPLive! Don't miss these invigorating discussions on unanswered questions in #MDS, #CLL, #MPN, and more. Andrew Brunner Dr. Uma Borate: Associate Professor Sanam Loghavi, MD صنم لغوی 🔬🧬 Mohamed Kharfan-Dabaja, MD, MBA Binod Dhakal Urshila Durani ➡️ buff.ly/aqAdABO

The most impressive myeloma abstract at #ASCO25 Outstanding longterm efficacy with cilta-cel CAR-T. 5 year survival rate 50% 5 year PFS rate of 33% Astounding given multi-drug relapsed refractory setting. Plasma Cell Pete Noopur Raje Tom Martin Yi Lin Deepu Madduri

#ASCO25 And another one! Journal of Clinical Oncology: 5-yr CARTITUDE-1 results for cilta-cel CAR-T. 97 pts, 6 prior #MMsm lines, treated 2018-2019. All likely would have died; instead, 1/3 alive & well 5 yrs out with no maintenance! 👏 Beginning of the end for #plateauenvy? (cc Nina Shah)

Fantastic results! Great news for the patients!

Kudos to the sponsor and the investigators for this dedicated study in an unmet group!

Congrats Rakesh Popat on your great presentation! Very promising early results that could be disruptive in the clinic!

Sonrotoclax in MM story continues.. #icml2025; #icml18

Molecular and Immunological Determinants of Long-Term Survival in Multiple Myeloma | Blood Advances | American Society of Hematology ⁦Medical College of Wisconsin⁩ ⁦MCW Cancer Center⁩ ashpublications.org/bloodadvances/…

Excited to give a talk on zevor-cel and other novel CAR-T in MM; “Academic Exchange” Shanghai,China! ⁦Medical College of Wisconsin⁩ ⁦MCW Cancer Center⁩

Molecular and Immunological Determinants of Long-Term Survival in Multiple Myeloma [Jul 17, 2025] Kasomva et al. Blood Journals Portfolio ashpublications.org/bloodadvances/… #mmsm #ImmunoOnc #IDonc #LymphoidNeoplasia

Great day sharing ideas, research, and debates on #myeloma with Binod Dhakal and colleagues at MMSparks event in @merida #CureMyeloma #mmsm #MedEd #medtwitter #CART #bispecifics #MyelomaMexico #MyelomaFriends

Real‐World Treatment Patterns and Outcomes in Patients With Relapsed/Refractory Multiple Myeloma and 1–3 Prior Lines of Therapy: Optum Database - Dhakal - 2025 - Cancer Medicine - Wiley Online Library onlinelibrary.wiley.com/doi/10.1002/ca…